Under the deal, Agendia’s oncology biomarker technology will be used in the evaluation of new pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials.
Agendia president and CEO David Macdonald said the early stage research collaboration represents a potential new area for additional commercialization and expansion of the company’s platform technology.
"We are very pleased to apply our expertise to assist with the potentially groundbreaking work being done by Daiichi Sankyo," Macdonald said.
"With this new agreement, our molecular diagnostics technology will now be applied to additional areas of oncology research."
Both the companies have not disclosed the terms and other aspects of the agreement.
Daiichi Sankyo is focused in the creation and supply of new pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.